Goodbye TAIS and thanks for all the information! by McGuire, Treasure M. & Patounas, Marea
| VOLUME 33 | NUMBER 5 | OCTOBER 2010 147www.austral ianprescriber.com
Goodbye TAIS and thanks for all the 
information!
Treasure M McGuire, Assistant Director of Pharmacy, Mater Health Services, and 
Conjoint Senior Lecturer, School of Pharmacy, University of Queensland, Brisbane, and 
Associate Professor of Pharmacology, Faculty of Health Sciences and Medicine, Bond 
University, Queensland; Marea Patounas, Team Leader, Medicines Contact Centre, 
Mater Pharmacy Services, Mater Health Services, Brisbane 
Summary 
The Therapeutic Advice and Information 
Service was funded by the National Prescribing 
Service to provide a national drug information 
service for health professionals working in the 
community. For ten years the service achieved 
high levels of client satisfaction, and reached 
its contracted target of 6000 enquiries about 
medicines per year, however the service ceased 
on 30 June 2010. 
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Introduction
The National Medicines Policy states that 
… consumers and health practitioners should have timely 
access to accurate information and education about 
medicines and their use.1
The National Prescribing Service (NPS) launched the 
Therapeutic Advice and Information Service (TAIS) for health 
professionals in June 2000. This was a telephone service with 
an email and online enquiry facility, which aimed to give health 
professionals working in the community access to therapeutic 
information and advice.
The nationwide service was provided by a consortium of six 
hospital-based drug information centres under a single contract 
with the NPS. These centres offered specialised resources and 
access to clinical consultants. Their different locations provided 
extended coverage across Australia's time zones. Service 
provision automatically switched between participating centres 
for two-hour blocks across five states. The model gave callers 
nationwide access to a single pharmacist operator, Monday to 
Friday between 9 am and 7 pm AEST*, via a 1300 number and 
online. 
* Australian Eastern Standard Time
TAIS activity
TAIS could handle complex clinical questions through access to 
specialist drug information expertise and additional resources 
not readily available outside of hospitals. The service provided 
timely and tailored responses to questions such as those 
about comparisons within and across therapeutic classes, 
non-approved indications, complementary medicines, drugs 
marketed overseas, the likely outcomes of polypharmacy, and 
prescribing in pregnancy and children.
TAIS handled over 56 000 enquiries about medicines. Most 
were from community pharmacists and general practitioners 
(see Table 1). Approximately a third of enquiries were from 
practitioners in rural or remote parts of Australia. More than 
85% of enquiries were about an individual patient. The average 
enquiry was 31 minutes (range 15 minutes to 16 hours). This 
included phone time, literature review, collation, data entry and 
provision of a response.
Calls most frequently involved drugs used in psychiatry (15%), 
cardiovascular medicine (11%), infection (10%) and neurology 
(10%). Complementary medicines accounted for 8% of calls. 
These enquiries were commonly related to medication safety 
issues, such as drug interactions (19%), adverse drug reactions 
(18%), dosing or administration (11%), and pregnancy or 
lactation (8%). Enquiries about optimising therapeutic strategies 
Table 1
Callers seeking therapeutic advice, June 2000–June 2009
Community pharmacists 38%
General practitioners 33%
Specialists 11%
Consultant pharmacists 5%
NPS facilitators and staff 4%
Hospital pharmacists 4%
Nurses 3%
Allied health professionals 2%
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constituted 16% of calls. Table 2 shows examples of typical 
questions answered by TAIS.
TAIS adopted a quality management approach and adhered to 
professional2 and contact centre standards.3 Every two months 
a peer review committee audited a random 2% sample of 
enquiries. Between 2004 and 2009, 315 callers, of 633 surveyed, 
gave feedback. Of these, 97% reported that 'overall the 
information provided met my needs' and 40% stated a change 
in therapy had occurred as a consequence of advice from TAIS. 
TAIS closure 
The service could answer approximately 6000 calls annually, 
and operated at maximum capacity for a number of years.  
Over the life of the service, the funding provided amounted to 
a cost per call of $52, however this did not cover all costs of 
service provision. TAIS was able to capitalise on shared use of 
existing infrastructure, training and resources at individual sites. 
Although the service was of high quality and valued by its users, 
the NPS concluded that the model was no longer sustainable, 
and discontinued funding on 30 June 2010. 
While there will be no telephone service to replace TAIS, the 
NPS has provided a 'Guide to medicines information resources' 
for health professionals. This is available on the NPS website 
at www.nps.org.au/health_professionals/guide_to_medicines_
information_resources.
Lessons learned
For a decade, TAIS supported health professionals across 
Australia by providing timely access to quality therapeutic 
information and advice to support the quality use of medicines. 
Over this time, delivery of healthcare in the primary-care 
sector has become more demanding, with patients of greater 
complexity with multiple morbidities and medications. This 
trend is likely to continue and any future therapeutic advice 
and information service should be designed to be able to meet 
these changing complex needs. If a national drug information 
service is available in the future, it must be part of a coordinated 
effort to support the quality use of medicines in this dynamic 
environment. 
Table 2
Typical enquiries for therapeutic advice
Adverse reactions n Which antidepressant causes least weight gain? (GP)
n Which selective serotonin reuptake inhibitor or serotonin noradrenaline reuptake inhibitor 
causes the least amount of sexual dysfunction? (Specialist)
Interactions n How clinically significant is the interaction between clopidogrel and proton pump inhibitors? 
Should all patients avoid this combination? (Hospital pharmacist)
n What is the interaction between methotrexate and amoxycillin (flagged in dispensing software)? 
(Pharmacist)
Optimising therapeutic 
strategy
n Is a wash-out period required when switching from St John's wort to venlafaxine, if the patient 
has only been on St John's wort for five days? (GP)
n Which antimalarial(s) are recommended as prophylaxis in Papua New Guinea? Patient is 
trekking Kokoda track for 15 days (GP)
Pregnancy/lactation n Patient is six weeks pregnant taking venlafaxine, valaciclovir, sumatriptan and temazepam. 
Should she be screened for malformations? (GP)
n Could desvenlafaxine reduce fertility if taken by the male partner? (Specialist)
n Is an extract of marshmallow, garlic and echinacea safe when breastfeeding a six-week-old 
infant? (Nurse)
Complementary and 
alternative medicines
n What dose of melatonin is recommended to treat insomnia in a visually impaired three year 
old? (Specialist)
n Is glucosamine safe for a patient with diabetes? (NPS Facilitator)
n Can 'Cordyceps', a Chinese herb, be used to prevent colds? (GP)
Illicit drugs n Patient uses ecstasy and cocaine. What is the safety if citalopram is also used? (GP)
Foreign trade names n What is the equivalent to thiamazole (Chinese female taking 10 mg daily for hyperthyroidism)? 
(GP)
n What is the equivalent brand of Belara oral contraceptive pill (South American patient)? (GP)
New drugs n Can H1N1 vaccine be given if there is history of a severe reaction to tetanus vaccine? (Nurse)
n Is H1N1 vaccine live? Patient takes methotrexate (Specialist)
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Access to a drug information pharmacist, with expertise in 
retrieval and interpretation of therapeutic evidence, presents 
an opportunity to assist health professionals make timely and 
appropriate decisions about medicines for the individual patient 
and avoid harm from medicines. While a national service can 
provide access to this expertise for health professionals working 
outside hospitals, and enhance collegial relationships between 
health professionals, it requires significant resources to establish 
and maintain. A key challenge is to develop a service model that 
provides for long-term viability and achieves maximum value 
for the investment required. 
Achieving the cost-effective delivery of therapeutic information 
and advice requires careful consideration of the processes 
and systems used for responding to individual enquiries. The 
relative merits of a multi-site versus single-site service model 
were considered. The TAIS multi-site experience demonstrated 
that the advantages of sharing workload, resources, leave 
cover, and providing extended service hours across time zones 
exceeded any duplication disadvantages at a comparable cost. 
While documentation of enquiries and responses is important 
for quality assurance and evaluation, it is time-consuming and 
therefore costly. Sophisticated technological solutions are likely 
to improve efficiency, but must be sufficiently flexible to adapt 
to changing needs. The service model must also have capacity 
to allow for fluctuations in demand.
Systems should be in place to allow timely sharing and analysis 
of enquiry and response data. This can inform other quality use 
of medicines activities by identifying medicines information 
needs and emerging areas of controversy or uncertainty. 
While TAIS did use a database to record and report questions 
and answers, its construction did not allow for straightforward 
analysis on demand. Any future services should consider 
potential uses for information captured when designing or 
adapting a database. Answers to frequently asked questions 
should be made available to health professionals – for example, 
as decision support in clinical software – as a means of 
managing enquiry demand, allowing the service to focus on 
responding to complex or unusual requests. Information should 
also be shared more broadly between centres to improve 
efficiency and provide for a more consistent national approach.
Measuring the value and utility of a service for clinicians, and its 
impact on patient outcomes, may be difficult and expensive, yet 
it is important for ongoing service improvement and, possibly, 
for funding. Evaluation methods need to be planned during 
service model development, adequately resourced and focused 
on the service's aims to improve health outcomes. 
Conclusion
TAIS expertly responded to health professional enquiries 
over the past 10 years and provided many lessons for any 
future national therapeutic advice and information service. 
A service such as TAIS presents an opportunity to support 
health professionals to provide high quality information and 
advice to individual patients and to inform other quality use of 
medicines activities through collection and analysis of enquiry 
data. However, any such service must be carefully designed and 
evaluated to ensure the most efficient use of funding to improve 
patient outcomes.
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